News
Gilead pays Kymera $45 M to glue preclinical protein degrader onto burgeoning oncology pipeline
2+ hour, 28+ min ago (359+ words) Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise its option on Kymera Therapeutics" preclinical anticancer molecular glue degrader. The pharmapaid Kymera $40 million for the exclusive option back in June…...
With $2 B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEO
1+ day, 3+ hour ago (677+ words) Despite signing a deal potentially worth $2. 1 billion, Vivtex Therapeutics CEO Thomas von Erlach, Ph. D. , refuses to rest on his laurels. While the biotech may be best known for its high-profile oral delivery partnership, the company is advancing several R&D…...
With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger"
1+ day, 7+ hour ago (1015+ words) After entering 2026 hungry for deals, Gilead Sciences has wasted no time eating its fill. Having swallowed CAR-T company Arcellx, T-cell engager-focused Ouro Medicines and antibody drug-conjugate (ADC) biotech Tubulis over just six weeks, the biopharma is now focused on digesting…...
Lilly pays AC Immune $12. 5 M to expand Alzheimer's collab as asset draws closer to clinic
2+ day, 1+ hour ago (454+ words) Eli Lilly has handed AC Immune 10 million Swiss francs ($12. 5 million) to expand their Alzheimer's disease collaboration as a candidate moves closer to the clinic. The U. S. pharma first tapped up AC Immune in a 2018 deal that included an $81 million upfront fee....
Takeda tears up Denali partnership, returning dementia asset amid restructuring
2+ day, 21+ hour ago (381+ words) Takeda has terminated a neuro partnership with Denali Therapeutics as the Japanese pharma undergoes a massive restructuring marked by significant layoffs. Takeda has handed back a dementia candidate called DNL593 to Denali, according to an April 3 filing with the Securities and…...
Google News
3+ day, 29+ min ago (14+ words) Zeto's latest EEG device garners FDA 510(k) clearance for outpatient use'Fierce Biotech...
Months after $100 M series A, Syneron closes $150 M round to support peptide platform
6+ day, 1+ hour ago (306+ words) After securing a multibillion-dollar biobucks deal with Astra Zeneca and raising nearly $100 million last year, peptide drug discovery company Syneron Bio has announced the closing of a $150 million series B round to support its macrocyclic peptide development platform. The round…...
Immunovant's Fc Rn inhibitor flunks phase 3 eye disease trials, validating biotech's waning interest
1+ week, 3+ hour ago (277+ words) Immunovant's first-generation Fc Rn inhibitor'flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of commercializing the drug. Patients in the studies were randomized to receive either the treatment or placebo. No new safety signals were…...
Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA
2+ week, 5+ hour ago (352+ words) Biopharma funding fell 20% last year, reversing the post-pandemic recovery as the IPO haul dropped to the lowest level of the past 10 years. IQVIA'shared the data in a report that tracked surges in the number of deals with Chinese biotechs and…...
Gilead's $2. 2 B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos
2+ week, 2+ day ago (540+ words) Gilead Sciences is paying $1. 67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. As well as the $1. 675 billion in upfront cash, Gilead has pledged up to $500 million in…...